Elevated Liver Enzymes in NAFLD: Causes and Clinical Implications

Primary Mechanism: Hepatocyte Injury from Fat Accumulation

Elevated liver enzymes in NAFLD result from hepatocyte injury caused by fat accumulation and subsequent lipotoxicity, with ALT and AST released into serum when hepatocytes are damaged by metabolic insults, inflammation, and oxidative stress, as recommended by the American College of Radiology 1
Initial fat accumulation develops from insulin resistance and metabolic syndrome, leading to excessive hepatic triglyceride storage, according to the Journal of Hepatology 2, 3
Inflammation develops in 25-30% of NAFLD cases when lipid-induced hepatocyte injury triggers inflammatory responses, as stated by the American College of Radiology 1

The AST:ALT ratio <1 is characteristic of NAFLD, contrasting with the ratio >2 seen in alcoholic liver disease, as recommended by the American College of Radiology 1
Mild aminotransferase elevations are typical, with NAFLD being the most common cause of mild enzyme increases, according to the American College of Radiology 1
ALT elevation is directly linked to hepatocyte injury severity, making it a more specific marker for metabolic liver disease, as stated by the American College of Radiology 1

Type 2 diabetes and metabolic syndrome are strongly associated with higher enzyme levels and more severe hepatocyte injury, as reported by the Journal of Hepatology 6
Obesity increases NAFLD prevalence to 70%, with more pronounced hepatic inflammation, according to the Journal of Hepatology 2
Insulin resistance is the central metabolic driver, present even in lean NAFLD patients, as stated by the Journal of Hepatology 3

NAFLD is the most common cause of unexplained elevated liver enzymes in developed countries, affecting 17-46% of adults, as reported by the Journal of Hepatology 2, 3
Screening for metabolic syndrome components and assessment for type 2 diabetes should be triggered by the presence of elevated enzymes, as recommended by the Journal of Hepatology 2, 3, 6
Evaluation for disease severity using fibrosis markers is necessary, as enzyme levels alone don't predict fibrosis stage, according to the Journal of Hepatology 6